Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]ASP0367 in Healthy Men
NCT05217901Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bocidelpar in Duchenne muscular dystrophy (DMD) and Mitochondrial myopathies (MM), sponsored by Astellas Pharma. Primary endpoints: Area Under The Concentration Time curve From The Time of Dosing Extrapolated to Time Infinity up to 12 days, Area Under The Concentration-time Curve From The Time of Dosing to The Last Measurable Concentration up to 12 days and 7 more. Started Jan 2022; status: completed.
02
Drugs
bocidelpar
03
Conditions
Duchenne muscular dystrophy (DMD)Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on NCT05217901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217901.